Is the cash price or the insurance price cheaper for a GLP-1?

It depends entirely on your plan. If your insurance covers the drug for weight loss, a copay — with the manufacturer's savings card, for commercially insured patients — can run $0 to $25 a month, far below any cash price. If it doesn't cover weight loss — which is common — the manufacturer's direct cash program is often cheaper than paying full retail, roughly $299 to $499 a month depending on drug and dose in late 2025.

Why won't my insurance cover a GLP-1 for weight loss?

Coverage for weight management is inconsistent by design. Medicare is barred by statute from covering drugs used solely for weight loss, and many employer plans exclude it or attach requirements like a BMI threshold or a lifestyle program. KFF found large-employer coverage rising but still far from universal. The same drug is more likely to be covered when prescribed for type 2 diabetes.

What is the telehealth platform's fee actually paying for?

Usually the clinician visit, prescription management, and customer service — not the drug. Read whether the quoted monthly price includes the medication or sits on top of it, and whether it auto-renews. Check how you cancel before you sign up; a platform that makes cancellation deliberately hard is a red flag regardless of the current federal rule.

What GLP-1s really cost online: cash-pay vs insurance

Shopping for a GLP-1 online in 2026 means untangling three different prices that get blurred together in marketing: what the drug costs, what your insurance will (or won’t) pay, and what the telehealth platform charges to put a clinician between you and the pharmacy. This is not medical advice — it’s a map for comparing offers without getting surprised on the second month’s bill.

The cash price finally dropped — and it’s public

For years the honest answer to “what does a GLP-1 cost cash?” was “over a thousand dollars a month.” That changed. In March 2025, Novo Nordisk launched NovoCare Pharmacy selling all doses of branded Wegovy (semaglutide) directly to cash-paying patients at $499 a month. By November 2025 the standard self-pay rate had dropped to $349, with a limited $199 introductory offer on the two lowest doses.

Eli Lilly followed with LillyDirect. As of December 1, 2025, self-pay single-dose vials of Zepbound (tirzepatide) run $299 a month for 2.5 mg, $399 for 5 mg, and $449 for all higher doses — down from $349 and $499.

Two things matter here. First, these are list cash prices straight from the manufacturer, so they’re the number to benchmark any telehealth quote against. Second, they’re for the FDA-approved branded drug — not the compounded versions many platforms pushed during the shortage. We cover why compounded pricing looks cheaper and what changed when the shortage ended separately.

Insurance for weight loss is a coin flip

If your plan covers a GLP-1 for weight management, you’ll usually beat any cash price. Novo says most commercially insured Wegovy patients pay $0 to $25 a month with its savings card. The problem is that coverage for weight loss specifically is inconsistent, and it’s inconsistent for structural reasons — not because you filled out a form wrong.

Medicare is prohibited by statute from covering drugs used for weight loss, though it can cover the same molecules for another approved condition such as type 2 diabetes or cardiovascular risk reduction.
Employer plans are split. KFF found that in 2025, 43% of firms with 5,000 or more workers covered GLP-1s for weight loss (up from 28% a year earlier), but coverage falls off sharply at smaller employers. Many that do cover attach conditions — a BMI cutoff, prior authorization, or mandatory enrollment in a lifestyle or dietitian program.

The practical upshot: the same drug, same dose, same person can be a low copay or a several-hundred-dollar cash purchase depending on which employer’s plan you’re on and whether the prescription is written for diabetes or obesity. Before you pay a platform anything, it’s worth calling your pharmacy benefit manager and asking whether the specific drug is on formulary for weight management and what hoops apply.

The platform fee is a third, separate charge

Here’s where telehealth quotes get slippery. A membership or “program” fee pays for the clinician visit, prescription handling, and support — it is usually not the drug. Some platforms bundle the medication into one monthly figure; others quote a low membership price and add the drug on top. A $99 “GLP-1 program” is not a $99 GLP-1.

When you compare offers, pin down four things: (1) does the quoted price include the medication or not; (2) is it the branded drug or a compounded product; (3) does the price change after an introductory period; and (4) how do you cancel. That last point has teeth. The FTC’s click-to-cancel rule was written to require sellers to make canceling a recurring subscription as easy as signing up and to disclose auto-renewal terms up front. The Eighth Circuit vacated that specific rule in July 2025 on procedural grounds, and the FTC has since moved to rewrite it, but negative-option enforcement by the FTC and state attorneys general continues — and a platform that makes cancellation deliberately hard is telling you something regardless of the rule’s status.

The bottom line

Run the comparison as three numbers, not one. Check whether your insurance covers the drug for weight loss; if it does, that copay usually wins. If it doesn’t, benchmark every telehealth offer against the manufacturer’s direct cash price — roughly $299 to $499 a month in late 2025 — and confirm whether the platform’s fee sits on top. For the consumer mechanics of starting and titrating, our sister site myglptalk.com goes deeper on the day-to-day; here we stay on what it costs and whether the offer is straight with you.